Avalon’s latest biotech closes $58M round as it pursues treatments for autoimmune brain conditions

Arialys Therapeutics announced Tuesday that it tied the bow on a $58 million seed round to develop treatments specifically for brain disorders caused by immune reactions.

Endpoints News reported in December that the CNS biotech was working on a $55 million round, which was backed by Avalon BioVentures, MPM Capital and Catalys Pacific. Johnson & Johnson’s venture capital arm and Alexandria Venture Investments also took part in the big seed round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Opinion | Federal Probes Need to Look Beyond Private Equity-Owned Healthcare for Alleged Abuse

Ron Harman King is CEO of Vanguard Communications, a healthcare marketing and practice management consulting firm, and author of “The Totally Wired Doctor: Social Media,

April 15, 2024

Hospital groups ask Congress to reform 340B program, crack down on contract pharmacy restrictions

Hospital groups are asking Congress to do a better job of overseeing the 340B drug discount program, and they are calling on lawmakers to step

August 8, 2023

Measles Cases in Several States: What’s Going On?

Several recent measles outbreaks have public health officials concerned — and are drawing attention to rising childhood vaccine exemptions and renewing calls for increased measles

January 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.